USA: Orexo
Germany: Servier
UK, France, Italy, Spain: Ethypharm
The world’s most researched digital therapy program for depression. Proven effective in 13 RCTs.
Clinically shown to significantly reduce depressive symptoms with a NNT of 3.6.
Fully automated treatment adapts to individual patient needs and fits into the therapy plans of providers, payers and employers.
Developed by GAIA AG’s multidisciplinary team of experts in medicine, clinical psychology, psychotherapy and software development.
Provides Cognitive Behavioral Therapy (CBT) and other effective psychotherapeutic techniques.
Tailored to specific patient needs and cognitive capabilities. Accessible across all devices, anytime, anywhere.
RCTs demonstrate deprexis®’ effectiveness, safety and suitability.
Nine independent studies conducted with deprexis® have demonstrated its effectiveness and have confirmed the increase in benefits when deprexis® is added to existing care plans.
Bonnet et al. (2018) Zwerenz et al. (2017) Berger et al. (2017) Beevers et al. (2017) Klein et al. (2016) Meyer et al. (2015) Moritz et al. (2012) Berger et al. (2011) Meyer et al. (2009)
Depression is especially prevalent in patients with severe medical conditions and disorders. deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.
Bücker et al. (2018) Fischer et al. (2015) Schröder et al. (2014)
A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.
Gräfe et al. (2020)
Multiple meta-analyses and systematic reviews have confirmed the scientific evidence gathered in 13 RCTs that deprexis® is an effective treatment for depression.
Twomey et al. (2020) Rogers et al. (2017) Karyotaki et al. (2017) Johansson & Andersson (2012) Richards & Richardson (2012) Cuijpers et al. (2011)
USA: University of Texas, Austin; Cedars Sinai Medical Center Los Angeles; University of Massachusetts Medical School
SWEDEN: The Karolinska Institute; Linkoping University
GERMANY: Universitätsklinikum Hamburg-Eppendorf (UKE); Charite Universitätsmedizin Berlin; Universität Trier; Universität Tübingen
UK: University of Cambridge; Kings College London; City University, London
FUNDING PARTNERS: the U.S. department of veteran affairs, the U.S. national multiple sclerosis society, the European Union, the European Commission, the German ministry of health, and the Brain and Behavior Research Foundation, the German Association of Psychotherapists (DPTV), major German health insurance companies and several other research centers, universities and hospitals across Europe, the U.S. and other regions.
Hans-Henny-Jahnn-Weg 53
22085 Hamburg
Germany
Vertretungsberechtigter Vorstand:
Registergericht:
Registernr.:
USt-IdNr.:
Intended Purpose:
EU and Switzerland: deprexis is intended to provide therapeutic methods and exercises based on evidence-based psychological and psychotherapeutic therapies for patients with unipolar depression or depressive disorders, to help them managing their depression or depressive disorder. deprexis is intended as a self-application supplemental to care-as-usual for patients 18 years of age or older. deprexis can be used for a period of 90 days. deprexis is neither intended to replace treatment provided by a health care provider nor to provide information which is used to take decisions with diagnosis or therapeutic purposes.
USA: deprexis is web application indicated for the adjunctive treatment of chronic or recurrent depression or depressive disorders as a primary or secondary diagnosis (e.g. as a comorbidity in multiple sclerosis or epilepsy) for patients 18 years of age or older who are experiencing a depressive episode.
